MAIA Biotechnology
MAIA
19 hedge funds and large institutions have $3.49M invested in MAIA Biotechnology in 2025 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 5 increasing their positions, 3 reducing their positions, and 4 closing their positions.
67% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 3
0.34% less ownership
Funds ownership: 7.54% → 7.19% (-0.34%)
5% less funds holding
Funds holding: 20 → 19 (-1)
12% less capital invested
Capital invested by funds: $3.95M → $3.49M (-$465K)
25% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Marshall Wace
London,
United Kingdom
|
+$154K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$79.8K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$19K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$3.56K |
| 5 |
CW
Curio Wealth
Annapolis,
Maryland
|
+$3.27K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$61.5K |
| 2 |
Jane Street
New York
|
-$51.8K |
| 3 |
Morgan Stanley
New York
|
-$6.96K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$3.82K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$330 |
MAIA Hedge Fund Activity: Q3 2025 in Review
19 of the 7,621 institutional investors tracked by Wall St. Rank reported a position in MAIA Biotechnology (MAIA) for Q3 2025, worth a combined $3.49M — down 12% from $3.95M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of MAIA and 3 opened new positions — a net loss of 1 holder — while 3 trimmed existing stakes and 5 added.
The largest buyer was Marshall Wace, adding an estimated $154K. The largest seller was Vanguard Group, cutting an estimated $61.5K.
- 19 institutional investors held MAIA Biotechnology (MAIA) as of Q3 2025, down from 20 in Q2 2025.
- Funds reported $3.49M of MAIA Biotechnology stock for Q3 2025, down 12% quarter-over-quarter.
- 3 funds opened new MAIA Biotechnology positions in Q3 2025 and 4 closed out, a net change of -1 holder.
- The largest MAIA Biotechnology buyer in Q3 2025 was Marshall Wace, an estimated $154K added.
- The largest MAIA Biotechnology seller in Q3 2025 was Vanguard Group, an estimated $61.5K sold.
Based on aggregated 13F filings for Q3 2025.